Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
MAIA Biotechnology, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
MAIA
NYSE American
2834
maiabiotech.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for MAIA Biotechnology, Inc.
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
- Jun 18th, 2026 6:30 am
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
- Jun 10th, 2026 7:15 am
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
- Jun 4th, 2026 7:45 am
Sector Update: Healthcare Stocks Higher Late Afternoon
- Jun 3rd, 2026 1:43 pm
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
- Jun 3rd, 2026 7:45 am
MAIA Biotechnology Announces Open Market Purchases by CEO and Director
- Jun 2nd, 2026 7:45 am
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
- Jun 1st, 2026 6:00 am
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
- May 18th, 2026 6:00 am
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
- Apr 16th, 2026 7:20 am
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
- Apr 8th, 2026 7:00 am
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
- Mar 31st, 2026 7:15 am
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
- Mar 4th, 2026 2:00 pm
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
- Mar 2nd, 2026 8:45 pm
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- Mar 2nd, 2026 3:00 pm
MAIA Biotechnology’s Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
- Feb 24th, 2026 6:45 am
MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum
- Jan 20th, 2026 8:15 am
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
- Dec 24th, 2025 6:01 am
MAIA Biotechnology Announces $1.51 Million Private Placement
- Dec 16th, 2025 2:15 pm
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
- Dec 11th, 2025 11:00 am
MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
- Dec 11th, 2025 7:00 am
Scroll